Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients

Nephrology Dialysis Transplantation

Volumn 31, Issue 4, 2016, Pages 619-627

  Campbell, Denise J ^a,b   Brown, Fiona G ^c   Craig, Jonathan C ^a,b   Gallagher, Martin P ^d   Johnson, David W ^e   Kirkland, Geoffrey S ^f   Kumar, Subramanian K ^g   Lim, Wai H ^h   Ranganathan, Dwarakanathan ⁱ   Saweirs, Walaa ^j,k   Sud, Kamal ^l,m   Toussaint, Nigel D ^n,o   Walker, Rowan G ^o,p   Williams, Lesley A ⁱ   Yehia, Maha ^q   Mudge, David W ^e  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ROYAL HOBART HOSPITAL   (Australia)

^g GOSFORD HOSPITAL   (Australia)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^j WHANGAREI HOSPITAL   (New Zealand)

^k UNIVERSITY OF AUCKLAND   (New Zealand)

^l UNIVERSITY OF SYDNEY   (Australia)

^m Westmead and Nepean Hospitals   (Australia)

ⁿ WESTERN HEALTH   (Australia)

^o ROYAL MELBOURNE HOSPITAL   (Australia)

^p ALFRED HOSPITAL   (Australia)

^q AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

antibiotic; antifungal agents; catheters indwelling; peritoneal dialysis; peritonitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFAZOLIN; CEFUROXIME; PSEUDOMONIC ACID; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRALIAN; CATHETER INFECTION; COMMUNICATION SKILL; CONSENSUS; DRUG COST; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NEPHROLOGIST; NEW ZEALANDER; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROTOCOL COMPLIANCE; ADVERSE EFFECTS; CLINICAL PRACTICE; CLINICAL TRIAL; INDWELLING CATHETER; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY;

AGED; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; CATHETERS, INDWELLING; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES;

EID: 84965183078     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv115     Document Type: Article

References (24)

1. National Health Service (NHS) Executive. Promoting Clinical Effectiveness: A Framework for Action in and Through the NHS. Leeds: Department of Health; 1996
2. McGlynn E, Asch S, Adams J et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348: 2635-2645
3. Grol R, Wensing M. What drives change? Barriers to and incentives for achieving evidence-based practice. Med J Aust 2004; 180(6 Suppl): S57-S60
4. Brown F, Gulyani A, McDonald S et al. Peritoneal dialysis. In: McDonald S, Clayton P, Hurst K, (eds). ANZDATA Registry Report 2012. Adelaide, SA: ANZDATA Registry; 2013, pp. 6-1-6-32
5. Jose MD, Johnson DW, Mudge DWet al. Peritoneal dialysis practice in Australia and New Zealand: A call to action. Nephrology 2011; 16: 19-29
6. Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis 2014; 64: 278-289
7. JohnsonDW, Excell L, Livingston B et al. Peritoneal dialysis. In: McDonald S, Excell L, Livingston B, (eds). ANZDATA Registry Report 2008. Adelaide, SA: ANZDATA Registry; 2009, pp. 6-1-6-20
8. Li PK-T, Szeto CC, Piraino B et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30: 393-423.
9. Erratum appears in Perit Dial Int. 2011; 31(5):512]
10. Brown F, Gulyani A, DentHet al. Peritoneal dialysis. In: McDonald S, Clayton P, Hurst K, (eds). ANZDATA Registry Report 2011. Adelaide, SA: ANZDATA Registry; 2012, pp. 6-1-6-32
11. Badve S, Smith A, Hawley Cet al. Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients [letter]. Nephrol Dial Transplant Plus 2009; 2: 508
12. Walker A, Bannister K, George C et al. KHA-CARI guideline: peritonitis treatment and prophylaxis. Nephrology (Carlton) 2014; 19: 69-71
13. Bannister K, Brown F, Chow J et al. CARI guideline: evidence for peritonitis treatment. Nephrology (Carlton) 2004; 9(Suppl 3): S41-S106
14. Piraino B, Bernardini J, Brown E et al.ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31: 614-630
15. Institute for Healthcare Improvement. Cause and effect diagram [Website]. 2004 http://www.ihi.org/resources/Pages/Tools/CauseandEffectDiagram. aspx (30 July 2014, date last accessed)
16. Lim CT-S, Wong K-S, Foo MW-Y. The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. Nephrol Dial Transplant 2005; 20: 2202-2206
17. Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 2006; 70: S55-S62.
18. Kopriva-Altfahrt G, Konig P, Mundle M et al. Exit-site care in Austrian peritoneal dialysis centers-a nationwide survey. Perit Dial Int 2009; 29: 330-339
19. Luzar M, Coles G, Faller B et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.N Engl J Med 1990; 322: 505-509
20. Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the United States? Milbank Q 1998; 76: 517-563, 09
21. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001; 39(8 Suppl 2): II46-II54
22. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. The Lancet 2003; 362: 1225-1230
23. National Institute of Clinical Studies (NICS). The NICS barrier tool. Melbourne: NICS; 2005 http://www.nhmrc.gov.au/-files-nhmrc/file/nics/material-resources/NICS%20Barrier%20Tool.pdf (11 March 2014, date last accessed)
24. Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS): Volume 5-Remoteness Structure (cat no. 1270.0.55.005) Canberra; 2011